Pharmaceutical Industry Archives – Page 2 of 4

Time for $5 Coalition Statement: Cepheid’s Updated GeneXpert Pricing Does Not Address Country Needs

May 10, 2021
Dorrit Walsh

The Time for $5 Coalition, comprised of over 150 civil society organizations globally, calls out Cepheid for the company’s insufficient and self-serving GeneXpert pricing packages for low- and middle-income countries (LMICs), announced May 6, 2021.

Treatment Action Group Statement on Early Findings from HPTN 084

November 12, 2020
Dorrit Walsh

Treatment Action Group welcomes the announcement that the phase 3 HPTN 084 trial proved that intramuscular injections of ViiV’s long acting cabotegravir (CAB-LA) every eight weeks were superior to daily oral TDF/FTC pre-exposure prophylaxis (PrEP) in preventing new HIV infections in cisgender women in sub-Saharan Africa.

Treatment Action Group and AVAC Statement on Pfizer/BioNTech COVID-19 Vaccine Efficacy Announcement

November 9, 2020
Dorrit Walsh

Treatment Action Group (TAG) and AVAC welcome today’s announcement that preliminary data from the efficacy trial of Pfizer/BioNTech’s mRNA COVID-19 vaccine indicates a high level of protection against COVID-19. Our organizations urge caution, however, given the very limited information that is available only through a company press release.

Advancing Access through Market Interventions: Lessons Learned from the GeneXpert Tuberculosis Test Buy-Down

September 21, 2020
Dorrit Walsh

This policy brief examines lessons learned from the Xpert MTB/RIF TB test buy-down and provides recommendations and pro-access conditions that should be applied to R&D funding, buy-down, and other market intervention agreements for COVID-19 diagnostics.

Public Investment in Bedaquiline Up to Five-Fold That of Johnson & Johnson

September 18, 2020
Dorrit Walsh

Treatment Action Group’s independent, peer-reviewed analysis found public investment in the development of bedaquiline was up to five times that of Johnson and Johnson. This finding appears in the new PLOS ONE article, “Public Investments in the Clinical Development of Bedaquiline.”

Treatment Action Group Statement on Bedaquiline Unaffordability

July 6, 2020
Dorrit Walsh

Treatment Action Group welcomes the Global Drug Facility / Stop TB Partnership's negotiation of what amounts to a 32% savings on bedaquiline, the backbone of improved, all-oral regimens for treating drug-resistant TB.

Treatment Action Group and the PrEP4All Collaboration Respond to Reported Remdesivir Results for COVID-19

April 30, 2020
Dorrit Walsh

Treatment Action Group (TAG) and the PrEP4All Collaboration welcome results from randomized controlled trials of therapies for COVID-19, but are seriously concerned about claims that data from a National Institutes of Allergy and Infectious Diseases (NIAID) study of the Gilead drug remdesivir...

Treatment Action Group Statement on the High Price of Cepheid’s Xpert Test for COVID-19

March 27, 2020
Dorrit Walsh

Cepheid is profiteering during a pandemic, with dangerous consequences for countries with vulnerable populations and health systems. New York, March 27, 2020 — Treatment Action Group calls for Cepheid to immediately lower to US$ 5 the developing country price of…

The Future of Biomedical HIV Prevention Trials: Researcher Viewpoints and Community Survey

March 6, 2020
Dorrit Walsh

This report aims to make more accessible to community advocates discussions around ethical conduct of biomedical prevention trials in the era of PrEP. In early 2019, TAG, along with Black AIDS Institute and the HIV Vaccine Trials Network developed an…

Isoniazid/Rifapentine (3HP) Access Roadmap and Patent Landscape

March 3, 2020
Dorrit Walsh

Our publication, Isoniazid/Rifapentine (3HP) Access Roadmap and Patent Landscape, provides a landscape of patent applications filed by the French pharmaceutical company Sanofi on combinations of two essential medicines used to prevent tuberculosis (TB): isoniazid and rifapentine.